Antiplatelet and anticoagulation therapy for acute coronary syndromes (Q26824701)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Robert A Harrington

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

1 reference

6 June 2014

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

114

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

12

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

1929-1943

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Aspirin dose for the prevention of cardiovascular disease: a systematic review

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Antithrombotic strategies to reduce adverse clinical outcomes in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Aspirin resistance: more than just a laboratory curiosity

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in plat

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Platelet inhibition with cangrelor during PCI

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Intensifying platelet inhibition--navigating between Scylla and Charybdis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Bivalirudin for patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Facilitated PCI in patients with ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Bivalirudin during primary PCI in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Early versus delayed, provisional eptifibatide in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Platelet inhibition with cangrelor in patients undergoing PCI.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Intravenous platelet blockade with cangrelor during PCI.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Clopidogrel with or without omeprazole in coronary artery disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Apixaban with antiplatelet therapy after acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Vorapaxar in the secondary prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Bivalirudin started during emergency transport for primary PCI.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

1 reference

7 January 2021

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Clinical aspects of platelet inhibitors and thrombus formation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Pathophysiology of coronary artery disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Antiplatelet therapy and proton pump inhibition: clinician update

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.302737

7 January 2021

10.1161/CIRCRESAHA.114.302737

Identifiers

DOI

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24902976%20AND%20SRC:MED&resulttype=core&format=json

release_yoeandmawzfz7csa6f3kjgdmaq

7 June 2020

Fatcat ID

0 references

2 references